Celularity (CELU) Change in Account Payables (2020 - 2025)
Celularity (CELU) posted quarterly Change in Account Payables of $1.8 million for Q4 2025, down 76.85% year-over-year from $7.9 million in Q4 2024, and up 881.28% quarter-over-quarter from $187000.0 in Q3 2025.
Celularity (CELU) Change in Account Payables (2020 - 2025) Analysis & Trends
Celularity (CELU) has reported Change in Account Payables for 6 consecutive years, with $1.8 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Change in Account Payables fell 76.85% year-over-year to $1.8 million; the TTM figure through Dec 2025 stood at $3.1 million (down 66.17% YoY), while the FY2025 annual figure was $3.1 million, down 66.17% from the prior year.
- Change in Account Payables rose to $1.8 million in Q4 2025 per CELU's latest filing, from $187000.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $7.9 million in Q4 2024 and bottomed at -$3.2 million in Q4 2022.
- Historically, Change in Account Payables has averaged $1.0 million across 5 years, with a median of $931000.0 in 2024.
- Annual changes were most pronounced in 2021 — Change in Account Payables jumped 2033.77% — and 2022, when it tumbled 297.5%.
- Celularity's Change in Account Payables stood at $1.6 million in 2021, then sank by 297.5% to -$3.2 million in 2022, then surged by 153.71% to $1.7 million in 2023, then surged by 354.79% to $7.9 million in 2024, then tumbled by 76.85% to $1.8 million in 2025.
- Business Quant data shows CELU's Change in Account Payables at $1.8 million in Q4 2025, $187000.0 in Q3 2025, and $1.1 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Celularity | 20.99 Mn | 14.82 Mn | -3.27 Mn | 1.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.84 Mn |
| Dec 31, 2025 | 1.84 Mn |
| Sep 30, 2025 | 187,000.00 |
| Sep 30, 2025 | 187,000.00 |
| Jun 30, 2025 | 1.09 Mn |
| Jun 30, 2025 | 1.09 Mn |
| Mar 31, 2025 | 17,000.00 |
| Mar 31, 2025 | 17,000.00 |
| Dec 31, 2024 | 7.93 Mn |
| Dec 31, 2024 | 7.93 Mn |
| Sep 30, 2024 | 1.71 Mn |
| Sep 30, 2024 | 1.71 Mn |
| Jun 30, 2024 | 775,000.00 |
| Jun 30, 2024 | 775,000.00 |
| Mar 31, 2024 | -1.17 Mn |
| Mar 31, 2024 | -1.17 Mn |
| Dec 31, 2023 | 1.74 Mn |
| Dec 31, 2023 | 1.74 Mn |
| Sep 30, 2023 | 711,000.00 |
| Sep 30, 2023 | 711,000.00 |